| 词条 | Duloxetine | ||||||||||||||
| 释义 |
| Verifiedfields = changed | verifiedrevid = 460765928 | IUPAC_name = (+)-(S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine | image = Duloxetine.svg | image2 = Duloxetine-3D-ball-model.png | tradename = Cymbalta, others[1] | Drugs.com = {{drugs.com|monograph|duloxetine}} | MedlinePlus = a604030 | licence_EU = yes | licence_US = duloxetine | pregnancy_AU = B3 | pregnancy_US = C | legal_AU = S4 | legal_CA = Rx-only | legal_UK = POM | legal_US = Rx-only | routes_of_administration = By mouth | class = Serotonin–norepinephrine reuptake inhibitor | bioavailability = ~ 50% (32% to 80%) | protein_bound = ~ 95% | metabolism = Liver, two P450 isozymes, CYP2D6 and CYP1A2 | elimination_half-life = 12 hours | excretion = 70% in urine, 20% in feces | CAS_number_Ref = {{cascite|changed|CAS}} | CAS_number = 116539-59-4 | CAS_number2_Ref = {{cascite|changed|CAS}} | CAS_number2 = 136434-34-9 | index2_label = as HCl | ATC_prefix = N06 | ATC_suffix = AX21 | PubChem = 60835 | IUPHAR_ligand = 202 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB00476 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 54822 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = O5TNM5N07U | UNII2_Ref = {{fdacite|changed|FDA}} | UNII2 = 9044SC542W | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D07880 | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = 36795 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 1175 | PDB_ligand = 29E | C=18 | H=19 | N=1 | O=1 | S=1 | molecular_weight = 297.41456 g/mol | smiles = CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32 | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = ZEUITGRIYCTCEM-KRWDZBQOSA-N |drug_name=|alt=|caption=|type=|legal_status=|pregnancy_category= }}Duloxetine, sold under the brand name Cymbalta among others,[1] is a medication used to treat major depressive disorder, generalized anxiety disorder, fibromyalgia, and neuropathic pain.[2] It is taken by mouth.[2] Common side effects include dry mouth, nausea, feeling tired, dizziness, agitation, sexual problems, and increased sweating.[2] Severe side effects include an increased risk of suicide, serotonin syndrome, mania, and liver problems.[2] Antidepressant withdrawal syndrome may occur if stopped.[2] There are concerns that use during the later part of pregnancy can harm the baby.[2] It is a serotonin–norepinephrine reuptake inhibitor.[3] How it works is not entirely clear.[2] Duloxetine was approved for medical use in the United States in 2004.[2] It is available as a generic medication.[3] In the United States the wholesale cost per dose is about 0.20 USD as of 2018.[4] In 2016 it was the 48th most prescribed medication in the United States with more than 15 million prescriptions.[5] Medical usesThe main uses of duloxetine are in major depressive disorder, generalized anxiety disorder, neuropathic pain, chronic musculoskeletal pain, and fibromyalgia.[2][6][7][8] Duloxetine is recommended as a first line agent for the treatment of chemotherapy-induced neuropathy by the American Society of Clinical Oncology,[9] as a first-line therapy for fibromyalgia in the presence of mood disorders by the German Interdisciplinary Association for Pain Therapy,[10] as a Grade B recommendation for the treatment of diabetic neuropathy by the American Association for Neurology[11] and as a level A recommendation in certain neuropathic states by the European Federation of Neurological Societies.[12] A 2014 Cochrane review concluded that duloxetine is beneficial in the treatment of diabetic neuropathy and fibromyalgia but that more comparative studies with other medicines are needed.[13] The French medical journal Prescrire concluded that duloxetine is no better than other available agents and has a greater risk of side effects.[14] Thus they recommend against its general use.[14] Major depressive disorderDuloxetine was approved for the treatment of major depression in 2004. While duloxetine has demonstrated improvement in depression-related symptoms compared to placebo, comparisons of duloxetine to other antidepressant medications have been less successful. A 2012 Cochrane Review did not find greater efficacy of duloxetine compared to SSRIs and newer antidepressants. Additionally, the review found evidence that duloxetine has increased side effects and reduced tolerability compared to other antidepressants. It thus did not recommend duloxetine as a first line treatment for major depressive disorder, given the (then) high cost of duloxetine compared to inexpensive off-patent antidepressants and lack of increased efficacy.[15] Generic duloxetine became available in 2013.[16] Generalized anxiety disorderDuloxetine is more effective than placebo in the treatment of generalized anxiety disorder (GAD).[17] Major guidelines such as Maudsley Prescribing Guidelines,[18] and Canadian Psychiatric Association Guidelines[19] do not list duloxetine among the recommended treatment options. A review from the Annals of Internal Medicine lists duloxetine among the first line drug treatments, however, along with citalopram, escitalopram, sertraline, paroxetine, and venlafaxine.[20] Diabetic neuropathyDuloxetine was approved for the pain associated with diabetic peripheral neuropathy (DPN), based on the positive results of two clinical trials. The average daily pain was measured using an 11-point scale, and duloxetine treatment resulted in an additional 1–1.7 points decrease of pain as compared with placebo.[21][22][23] At least 50% pain relief was achieved in 40–45% of the duloxetine patients vs. 20–22% of placebo patients. Pain decreased by more than 90%, in 9–14% of duloxetine patients vs. 2–4% of placebo patients. Most of the response was achieved in the first two weeks on the medication. Duloxetine slightly increased the fasting serum glucose; this effect was deemed to be of "minimal clinical significance", however.[21] The comparative efficacy of duloxetine and established pain-relief medications for DPN is unclear. A systematic review noted that tricyclic antidepressants (imipramine and amitriptyline), traditional anticonvulsants and opioids have better efficacy than duloxetine. Duloxetine, tricyclic antidepressants and anticonvulsants have similar tolerability while the opioids caused more side effects.[24] Another review in Prescrire International considered the moderate pain relief achieved with duloxetine to be clinically insignificant and the results of the clinical trials unconvincing. The reviewer saw no reason to prescribe duloxetine in practice.[25] The comparative data collected by reviewers in BMC Neurology indicated that amitriptyline, other tricyclic antidepressants and venlafaxine may be more effective. The authors noted that the evidence in favor of duloxetine is much more solid, however.[26] A Cochrane review concluded that the evidence in support of duloxetine's efficacy in treating painful diabetic neuropathy was adequate, and that further trials should focus on comparisons with other medications.[13] Fibromyalgia and chronic painA review of duloxetine found that it reduced pain and fatigue, and improved physical and mental performance compared to placebo.[27] The U.S. Food and Drug Administration (FDA) regulators approved the drug for the treatment of fibromyalgia in June 2008.[28] It may be useful for chronic pain from osteoarthritis.[29][30] On November 4, 2010, the U.S. Food and Drug Administration approved duloxetine to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain.[31] Stress urinary incontinenceDuloxetine failed to receive US approval for stress urinary incontinence amid concerns over liver toxicity and suicidal events; it was approved for this use in the UK, however, where it is recommended as an add-on medication in stress urinary incontinence instead of surgery.[32] The safety and utility of duloxetine in the treatment of incontinence has been evaluated in a series of meta analyses and practice guidelines.
ContraindicationsThe following contraindications are listed by the manufacturer:[37]
In addition, the FDA has reported on life-threatening drug interactions that may be possible when co-administered with triptans and other drugs acting on serotonin pathways leading to increased risk for serotonin syndrome.[38] Adverse effectsNausea, somnolence, insomnia, and dizziness are the main side effects, reported by about 10% to 20% of patients.[39]In a trial for major depressive disorder (MDD), the most commonly reported treatment-emergent adverse events among duloxetine-treated patients were nausea (34.7%), dry mouth (22.7%), headache (20.0%) and dizziness (18.7%), and except for headache, these were reported significantly more often than in the placebo group.[40] In a long-term study of fibromyalgia patients receiving duloxetine, frequency and type of adverse effects was similar to that reported in the MDD above. Side effects tended to be mild-to-moderate, and tended to decrease in intensity over time.[41][42] In 4 clinical trials of duloxetine for the treatment of MDD, sexual dysfunction occurred significantly more frequently in patients treated with duloxetine than those treated with placebo, and this difference occurred only in men.[43][42] Specifically, common side effects include difficulty becoming aroused, lack of interest in sex, and anorgasmia (trouble achieving orgasm). Loss of or decreased response to sexual stimuli and ejaculatory anhedonia are also reported.[44] Frequency of treatment-emergent sexual dysfunction were similar for duloxetine and SSRIs when compared in a 6 month observational study in depressed patients.[45] Rates of sexual dysfunction in MDD patients treated with duloxetine vs escitalopram did not differ significantly at 4, 8, and 12 weeks of treatment, although the trend favored duloxetine (33.3% of duloxetine patients experienced sexual side effects compared to 43.6% of those receiving escitalopram and 25% of those receiving placebo).[44] Discontinuation syndrome{{Further|SSRI discontinuation syndrome}}During marketing of other SSRIs and SNRIs, there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as brain zap electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. The withdrawal syndrome from duloxetine resembles the SSRI discontinuation syndrome. When discontinuing treatment with duloxetine, the manufacturer recommends a gradual reduction in the dose, rather than abrupt cessation, whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate. In placebo-controlled clinical trials of up to nine weeks' duration of patients with MDD, a systematic evaluation of discontinuation symptoms in patients taking duloxetine following abrupt discontinuation found the following symptoms occurring at a rate greater than or equal to 2% and at a significantly higher rate in duloxetine-treated patients compared to those discontinuing from placebo: dizziness, nausea, headache, paresthesia, vomiting, irritability, and nightmare.[46] SuicidalityThe FDA requires all antidepressants, including duloxetine, to carry a black box warning stating that antidepressants may increase the risk of suicide in persons younger than 25. This warning is based on statistical analyses conducted by two independent groups of the FDA experts that found a 2-fold increase of the suicidal ideation and behavior in children and adolescents, and 1.5-fold increase of suicidality in the 18–24 age group.[47][48][49] To obtain statistically significant results the FDA had to combine the results of 295 trials of 11 antidepressants for psychiatric indications. As suicidal ideation and behavior in clinical trials are rare, the results for any drug taken separately usually do not reach statistical significance. In 2005 the United States FDA released a public health advisory noting that there had been 11 reports of suicide attempts and 3 reports of suicidality within the mostly middle-aged women participating in the open label extension trials of duloxetine for the treatment of stress urinary incontinence. The FDA described the potential role of confounding social stressors "unclear". The suicide attempt rate in the SUI study population (based on 9,400 patients) was calculated to be 400 per 100,000 person years. This rate is greater than the suicide attempt rate among middle-aged U.S. women that has been reported in published studies, i.e., 150 to 160 per 100,000 person years. In addition, one death from suicide was reported in a Cymbalta clinical pharmacology study in a healthy female volunteer without SUI. No increase in suicidality was reported in controlled trials of Cymbalta for depression or diabetic neuropathic pain.[50] Postmarketing reportsReported adverse events that were temporally correlated to duloxetine therapy include rash, reported rarely, and the following adverse events, reported very rarely: alanine aminotransferase increased, alkaline phosphatase increased, anaphylactic reaction, angioneurotic edema, aspartate aminotransferase increased, bilirubin increased, glaucoma, hepatotoxicity, hyponatremia, jaundice, orthostatic hypotension (especially at the initiation of treatment), Stevens–Johnson syndrome, syncope (especially at initiation of treatment), and urticaria.[51] PharmacologyMechanism of action
Duloxetine inhibits the reuptake of serotonin and norepinephrine (NE) in the central nervous system. Duloxetine increases dopamine (DA) specifically in the prefrontal cortex, where there are few DA reuptake pumps, via the inhibition of NE reuptake pumps (NET), which is believed to mediate reuptake of DA and NE.[53] Duloxetine has no significant affinity for dopaminergic, cholinergic, histaminergic, opioid, glutamate, and GABA reuptake transporters, however, and can therefore be considered to be a selective reuptake inhibitor at the 5-HT and NE transporters. Duloxetine undergoes extensive metabolism, but the major circulating metabolites do not contribute significantly to the pharmacologic activity.[54][55] Major depressive disorder is believed to be due in part to an increase in pro-inflammatory cytokines within the central nervous system. Antidepressants including ones with a similar mechanism of action as duloxetine, i.e. serotonin metabolism inhibition, cause a decrease in proinflammatory cytokine activity and an increase in anti-inflammatory cytokines; this mechanism may apply to duloxetine in its effect on depression but research on cytokines specific to duloxetine therapy is lacking.[56] The analgesic properties of duloxetine in the treatment of diabetic neuropathy and central pain syndromes such as fibromyalgia are believed to be due to sodium ion channel blockade.[57] PharmacokineticsAbsorption: Duloxetine is acid labile, and is formulated with enteric coating to prevent degradation in the stomach. Duloxetine has good oral bioavailability, averaging 50% after one 60 mg dose. There is an average 2-hour lag until absorption begins with maximum plasma concentrations occurring about 6 hours post dose. Food does not affect the Cmax of duloxetine, but delays the time to reach peak concentration from 6 to 10 hours.[55]Distribution: Duloxetine is highly bound (>90%) to proteins in human plasma, binding primarily to albumin and α1-acid glycoprotein. Volume of distribution is 1640L.[58]Metabolism: Duloxetine undergoes predominately hepatic metabolism via two cytochrome P450 isozymes, CYP2D6 and CYP1A2. Circulating metabolites are pharmacologically inactive.[58]Elimination: Duloxetine has an elimination half-life of about 12 hours (range 8 to 17 hours) and its pharmacokinetics are dose proportional over the therapeutic range. Steady-state is usually achieved after 3 days. Only trace amounts (<1%) of unchanged duloxetine are present in the urine and most of the dose (approx. 70%) appears in the urine as metabolites of duloxetine with about 20% excreted in the feces.[58]HistoryDuloxetine was created by Lilly researchers. David Robertson; David Wong, a co-discoverer of fluoxetine; and Joseph Krushinski are listed as inventors on the patent application filed in 1986 and granted in 1990.[59] The first publication on the discovery of the racemic form of duloxetine known as LY227942, was made in 1988.[60] The (+)-enantiomer of LY227942, assigned LY248686, was chosen for further studies, because it inhibited serotonin reuptake in rat synaptosomes to twice the degree of the (–)-enantiomer. This molecule was subsequently named duloxetine.[61] In 2001, Lilly filed a New Drug Application (NDA) for duloxetine with the US Food and Drug Administration. In 2003, however, the FDA "recommended this application as not approvable from the manufacturing and control standpoint" because of "significant cGMP (current Good Manufacturing Practice) violations at the finished product manufacturing facility" of Eli Lilly in Indianapolis. Additionally, "potential liver toxicity" and QTc interval prolongation appeared as a concern. The FDA experts concluded that "duloxetine can cause hepatotoxicity in the form of transaminase elevations. It may also be a factor in causing more severe liver injury, but there are no cases in the NDA database that clearly demonstrate this. Use of duloxetine in the presence of ethanol may potentiate the deleterious effect of ethanol on the liver." The FDA also recommended "routine blood pressure monitoring" at the new highest recommended dose of 120 mg, "where 24% patients had one or more blood pressure readings of 140/90 vs. 9% of placebo patients."[62] After the manufacturing issues were resolved, the liver toxicity warning included in the prescribing information, and the follow-up studies showed that duloxetine does not cause QTc interval prolongation, duloxetine was approved by the FDA for depression and diabetic neuropathy in 2004.[63] In 2007, Health Canada approved duloxetine for the treatment of depression and diabetic peripheral neuropathic pain.[64] Duloxetine was approved for use of stress urinary incontinence (SUI) in the EU in 2004. In 2005, Lilly withdrew the duloxetine application for stress urinary incontinence (SUI) in the U.S., stating that discussions with the FDA indicated "the agency is not prepared at this time to grant approval ... based on the data package submitted." A year later Lilly abandoned the pursuit of this indication in the U.S. market.[65][66] The FDA approved duloxetine for the treatment of generalized anxiety disorder in February 2007.[67] Cymbalta generated sales of nearly $5 billion in 2012 with $4 billion of that in the U.S., but its patent protection terminated January 1, 2014. Lilly received a six-month extension beyond June 30, 2013 after testing for the treatment of depression in adolescents, which may produce $1.5 billion in added sales.[68][69] It was the most prescribed antidepressant in 2013–14.[70] The first generic duloxetine was marketed by Dr. Reddy.[71] References1. ^1 {{cite web |title=Duloxetine |url=https://www.drugs.com/international/duloxetine.html |website=Drugs.com |accessdate=24 December 2018 |language=en}} 2. ^1 2 3 4 5 6 7 8 {{cite web | title = Duloxetine | work = Monograph| url = https://www.drugs.com/monograph/duloxetine.html | publisher = The American Society of Health-System Pharmacists| access-date = 2018-12-24}} 3. ^1 {{cite book|title=British national formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=364–365|edition=76}} 4. ^{{cite web |title=NADAC as of 2018-12-19 |url=https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-as-of-2018-12-19/g7bs-ahj4 |website=Centers for Medicare and Medicaid Services |accessdate=22 December 2018 |language=en}} 5. ^{{cite web |title=The Top 300 of 2019 |url=https://clincalc.com/DrugStats/Top300Drugs.aspx |website=clincalc.com |accessdate=22 December 2018}} 6. ^{{NICE|96|Neuropathic pain – pharmacological management|2010}} 7. ^{{cite journal | vauthors = Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, Feldman E, Iverson DJ, Perkins B, Russell JW, Zochodne D | title = Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation | journal = Neurology | volume = 76 | issue = 20 | pages = 1758–65 | date = May 2011 | pmid = 21482920 | pmc = 3100130 | doi = 10.1212/WNL.0b013e3182166ebe | displayauthors = etal }} 8. ^{{cite web|url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022516lbl.pdf|title=Cymbalta (duloxetine hydrochloride) Delayed-Release Capsules for Oral Use. }} 9. ^{{cite journal | vauthors = Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL | title = Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline | journal = Journal of Clinical Oncology | volume = 32 | issue = 18 | pages = 1941–67 | date = June 2014 | pmid = 24733808 | doi = 10.1200/JCO.2013.54.0914 | displayauthors = etal }} 10. ^{{cite journal | vauthors = Sommer C, Häuser W, Alten R, Petzke F, Späth M, Tölle T, Uçeyler N, Winkelmann A, Winter E, Bär KJ | title = [Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline] | language = German | journal = Schmerz | volume = 26 | issue = 3 | pages = 297–310 | date = June 2012 | pmid = 22760463 | doi = 10.1007/s00482-012-1172-2 | displayauthors = etal }} 11. ^{{cite journal | vauthors = Bril V, England JD, Franklin GM, Backonja M, Cohen JA, Del Toro DR, Feldman EL, Iverson DJ, Perkins B, Russell JW, Zochodne DW | title = Evidence-based guideline: treatment of painful diabetic neuropathy--report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation | journal = Muscle & Nerve | volume = 43 | issue = 6 | pages = 910–7 | date = June 2011 | pmid = 21484835 | pmc = 3100130 | doi = 10.1002/mus.22092 | displayauthors = etal }} 12. ^{{cite journal | vauthors = Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T | title = EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision | journal = European Journal of Neurology | volume = 17 | issue = 9 | pages = 1113-e88 | date = September 2010 | pmid = 20402746 | doi = 10.1111/j.1468-1331.2010.02999.x | displayauthors = etal }} 13. ^1 {{cite journal | vauthors = Lunn MP, Hughes RA, Wiffen PJ | title = Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia | journal = The Cochrane Database of Systematic Reviews | volume = 1 | issue = 1 | pages = CD007115 | date = January 2014 | pmid = 24385423 | doi = 10.1002/14651858.CD007115.pub3 }} 14. ^1 {{cite journal | vauthors = | title = Towards better patient care: drugs to avoid in 2014 | journal = Prescrire International | volume = 23 | issue = 150 | pages = 161–5 | date = June 2014 | pmid = 25121155 | url = http://english.prescrire.org/en/81/168/49342/0/NewsDetails.aspx }} 15. ^{{cite journal | vauthors = Cipriani A, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, Trespidi C, Barbui C | title = Duloxetine versus other anti-depressive agents for depression | journal = The Cochrane Database of Systematic Reviews | volume = 10 | pages = CD006533 | date = October 2012 | pmid = 23076926 | pmc = 4169791 | doi = 10.1002/14651858.cd006533.pub2 }} 16. ^{{cite journal |title=Loss of Cymbalta patent a major blow for Eli Lilly |journal=Indianapolis Star |date=2013-10-13 |last=Swiatek |first=Jeff |url=http://www.indystar.com/story/money/2013/12/10/loss-of-cymbalta-patent-a-major-blow-for-eli-lilly/3956997/ |access-date=2015-02-27 }} 17. ^{{cite journal | vauthors = Carter NJ, McCormack PL | title = Duloxetine: a review of its use in the treatment of generalized anxiety disorder | journal = CNS Drugs | volume = 23 | issue = 6 | pages = 523–41 | year = 2009 | pmid = 19480470 | doi = 10.2165/00023210-200923060-00006 }} 18. ^{{cite book |author1=Kerwin, Robert |author2=Taylor, David H. |author3=Carol Paton |title=Maudsley Prescribing Guidelines |publisher=Informa Healthcare |location= |year=2007 |page=254 |isbn=0-415-42416-X }} 19. ^{{cite journal | vauthors = | title = Clinical practice guidelines. Management of anxiety disorders | journal = Canadian Journal of Psychiatry | volume = 51 | issue = 8 Suppl 2 | pages = 9S-91S | date = July 2006 | pmid = 16933543 | doi = }} 20. ^{{cite journal | vauthors = Patel G, Fancher TL | title = In the clinic. Generalized anxiety disorder | journal = Annals of Internal Medicine | volume = 159 | issue = 11 | pages = ITC6–1, ITC6–2, ITC6–3, ITC6–4, ITC6–5, ITC6–6, ITC6–7, ITC6–8, ITC6–9, ITC6–10, ITC6–11; quiz ITC6–12 | date = December 2013 | pmid = 24297210 | doi = 10.7326/0003-4819-159-11-201312030-01006 }} 21. ^1 {{cite web | url = http://www.fda.gov/cder/foi/nda/2004/021733s000_Cymbalta_medr.pdf | title =Application number 21-733. Medical review(s).| access-date = 2009-04-14 | author = Josefberg H | date = 2004-09-03| format =PDF | publisher = FDA}} {{Dead link|date=November 2010|bot=H3llBot}} 22. ^{{cite journal | vauthors = Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S | title = Duloxetine vs. placebo in patients with painful diabetic neuropathy | journal = Pain | volume = 116 | issue = 1-2 | pages = 109–18 | date = July 2005 | pmid = 15927394 | doi = 10.1016/j.pain.2005.03.029 }} 23. ^{{cite journal | vauthors = Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, Wernicke JF | title = A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain | journal = Pain Medicine | volume = 6 | issue = 5 | pages = 346–56 | year = 2005 | pmid = 16266355 | doi = 10.1111/j.1526-4637.2005.00061.x | displayauthors = etal }} 24. ^{{cite journal | vauthors = Wong MC, Chung JW, Wong TK | title = Effects of treatments for symptoms of painful diabetic neuropathy: systematic review | journal = BMJ | volume = 335 | issue = 7610 | pages = 87 | date = July 2007 | pmid = 17562735 | pmc = 1914460 | doi = 10.1136/bmj.39213.565972.AE }} 25. ^{{cite journal | vauthors = | title = Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects | journal = Prescrire International | volume = 15 | issue = 85 | pages = 168–72 | date = October 2006 | pmid = 17121211 | doi = }} 26. ^{{cite journal | vauthors = Sultan A, Gaskell H, Derry S, Moore RA | title = Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials | journal = BMC Neurology | volume = 8 | pages = 29 | date = August 2008 | pmid = 18673529 | pmc = 2529342 | doi = 10.1186/1471-2377-8-29 }} 27. ^{{cite journal | vauthors = Acuna C | title = Duloxetine for the treatment of fibromyalgia | journal = Drugs of Today | volume = 44 | issue = 10 | pages = 725–34 | date = October 2008 | pmid = 19137126 | doi = 10.1358/dot.2008.44.10.1269675 }} 28. ^{{cite web |url=http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=316740 |title=FDA Approves Cymbalta for the Management of Fibromyalgia |date=2008-06-16 |work=Eli Lilly Co. |access-date=2008-06-17}} 29. ^{{cite journal | vauthors = Citrome L, Weiss-Citrome A | title = A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? | journal = Postgraduate Medicine | volume = 124 | issue = 1 | pages = 83–93 | date = January 2012 | pmid = 22314118 | doi = 10.3810/pgm.2012.01.2521 }} 30. ^{{cite journal | vauthors = Myers J, Wielage RC, Han B, Price K, Gahn J, Paget MA, Happich M | title = The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis | journal = BMC Musculoskeletal Disorders | volume = 15 | pages = 76 | date = March 2014 | pmid = 24618328 | pmc = 4007556 | doi = 10.1186/1471-2474-15-76 }} 31. ^{{cite web |url = http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm232708.htm |title = FDA clears Cymbalta to treat chronic musculoskeletal pain |publisher = Food and Drug Administration |date = 4 November 2010 |website = FDA Press Announcements |access-date= 19 August 2013 }} 32. ^{{NICE|40|Urinary incontinence|2006}} 33. ^{{cite journal | vauthors = Maund E, Guski LS, Gøtzsche PC | title = Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports | journal = CMAJ | volume = 189 | issue = 5 | pages = E194-E203 | date = February 2017 | pmid = 28246265 | pmc = 5289870 | doi = 10.1503/cmaj.151104 }} 34. ^{{cite journal | vauthors = Li J, Yang L, Pu C, Tang Y, Yun H, Han P | title = The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis | journal = International Urology and Nephrology | volume = 45 | issue = 3 | pages = 679–86 | date = June 2013 | pmid = 23504618 | doi = 10.1007/s11255-013-0410-6 }} 35. ^{{cite web|url=http://www.uroweb.org/gls/pdf/20%20Urinary%20Incontinence_LR.pdf|title=www.uroweb.org|format=|work=|access-date=|deadurl=yes|archive-url=https://web.archive.org/web/20140504105841/http://www.uroweb.org/gls/pdf/20%20Urinary%20Incontinence_LR.pdf|archive-date=2014-05-04|df=}} 36. ^{{cite web|url=http://publications.nice.org.uk/urinary-incontinence-cg171|title=Urinary incontinence Introduction CG171|format=|work=|access-date=|deadurl=yes|archive-url=https://web.archive.org/web/20140504105632/http://publications.nice.org.uk/urinary-incontinence-cg171|archive-date=2014-05-04|df=}} 37. ^{{cite web|url=http://www.cymbalta.com/learnaboutcymbalta/importantsafetyinformation.jsp|title=Eli Lilly and Company|publisher=}} 38. ^{{cite web|author=Report a Serious Problem |url=http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124915.htm |title=Information for Healthcare Professionals: Duloxetine (marketed as Cymbalta) – Selective Serotonin Reuptake Inhibitors (SSRIs) or Selective Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and 5-Hydroxytryptamine Receptor Agonists (Triptans) |publisher=Fda.gov |date=2013-08-14 |access-date=2013-09-18}} 39. ^Cymbalta package insert. Indianapolis, IN: Eli Lilly Pharmaceuticals; 2004, September. 40. ^{{cite journal | vauthors = Perahia DG, Kajdasz DK, Walker DJ, Raskin J, Tylee A | title = Duloxetine 60 mg once daily in the treatment of milder major depressive disorder | journal = International Journal of Clinical Practice | volume = 60 | issue = 5 | pages = 613–20 | date = May 2006 | pmid = 16700869 | pmc = 1473178 | doi = 10.1111/j.1368-5031.2006.00956.x | url = http://www.blackwell-synergy.com/doi/full/10.1111/j.1368-5031.2006.00956.x?cookieSet=1 }} 41. ^{{cite journal | vauthors = Chappell AS, Littlejohn G, Kajdasz DK, Scheinberg M, D'Souza DN, Moldofsky H | title = A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia | journal = The Clinical Journal of Pain | volume = 25 | issue = 5 | pages = 365–75 | date = June 2009 | pmid = 19454869 | doi = 10.1097/ajp.0b013e31819be587 }} 42. ^1 {{Cite news|url=https://www.drugs.com/pro/cymbalta.html|title=Cymbalta - FDA prescribing information, side effects and uses|work=Drugs.com|access-date=2018-09-14|language=en-US}} 43. ^{{cite journal | vauthors = Nelson JC, Lu Pritchett Y, Martynov O, Yu JY, Mallinckrodt CH, Detke MJ | title = The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials | journal = Primary Care Companion to the Journal of Clinical Psychiatry | volume = 8 | issue = 4 | pages = 212–9 | date = 2006 | pmid = 16964316 | pmc = 1557468 }} 44. ^1 {{cite journal | vauthors = Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M | title = Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder | journal = The Journal of Sexual Medicine | volume = 4 | issue = 4 Pt 1 | pages = 917–29 | date = July 2007 | pmid = 17627739 | doi = 10.1111/j.1743-6109.2007.00520.x }} 45. ^{{cite journal | vauthors = Dueñas H, Brnabic AJ, Lee A, Montejo AL, Prakash S, Casimiro-Querubin ML, Khaled M, Dossenbach M, Raskin J | title = Treatment-emergent sexual dysfunction with SSRIs and duloxetine: effectiveness and functional outcomes over a 6-month observational period | journal = International Journal of Psychiatry in Clinical Practice | volume = 15 | issue = 4 | pages = 242–54 | date = November 2011 | pmid = 22121997 | doi = 10.3109/13651501.2011.590209 }} 46. ^{{cite journal | vauthors = Perahia DG, Kajdasz DK, Desaiah D, Haddad PM | title = Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder | journal = Journal of Affective Disorders | volume = 89 | issue = 1-3 | pages = 207–12 | date = December 2005 | pmid = 16266753 | doi = 10.1016/j.jad.2005.09.003 }} 47. ^{{cite web |vauthors=Levenson M, Holland C | title = Antidepressants and Suicidality in Adults: Statistical Evaluation. (Presentation at Psychopharmacologic Drugs Advisory Committee; December 13, 2006)|access-date = 2007-05-13 | url = http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4272s1-04-FDA.ppt}} 48. ^{{cite web | url = http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf | title = Clinical review: relationship between antidepressant drugs and suicidality in adults| access-date = 2007-09-22 |vauthors=Stone MB, Jones ML | date = 2006-11-17| format =PDF | work = Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC) | publisher = FDA| pages = 11–74| quote = }} 49. ^{{cite web | url = http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf | title = Statistical Evaluation of Suicidality in Adults Treated with Antidepressants | access-date = 2007-09-22 |vauthors=Levenson M, Holland C | date = 2006-11-17| format =PDF | work =Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC) | publisher = FDA| pages = 75–140 }} 50. ^{{cite web |url=http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm114970.htm |title=Historical Information on Duloxetine hydrochloride (marketed as Cymbalta) |work= |access-date=}} 51. ^ {{Webarchive|url=https://web.archive.org/web/20080912150829/http://www.rxlist.com/cgi/generic/cymbalta_ad.htm |date=2008-09-12 }} Duloxetine Side Effects, and Drug Interactions – RxList Monographs 52. ^{{cite journal | vauthors = Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT | title = Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors | journal = Neuropsychopharmacology | volume = 25 | issue = 6 | pages = 871–80 | date = December 2001 | pmid = 11750180 | doi = 10.1016/S0893-133X(01)00298-6 | url = http://www.nature.com/npp/journal/v25/n6/full/1395741a.html }} {{open access}} 53. ^Stahl, S. (2013). Stahl's essential pharmacology, 4th ed. Cambridge University Press, New York. p. 305, 308, 309. 54. ^{{cite journal | vauthors = Stahl SM, Grady MM, Moret C, Briley M | title = SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants | journal = CNS Spectrums | volume = 10 | issue = 9 | pages = 732–47 | date = September 2005 | pmid = 16142213 }} 55. ^1 {{cite journal | vauthors = Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S | title = The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression | journal = Current Pharmaceutical Design | volume = 11 | issue = 12 | pages = 1475–93 | year = 2005 | pmid = 15892657 | doi = 10.2174/1381612053764805 }} 56. ^{{cite journal | vauthors = De Berardis D, Conti CM, Serroni N, Moschetta FS, Olivieri L, Carano A, Salerno RM, Cavuto M, Farina B, Alessandrini M, Janiri L, Pozzi G, Di Giannantonio M | title = The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature | journal = International Journal of Immunopathology and Pharmacology | volume = 23 | issue = 2 | pages = 417–22 | year = 2010 | pmid = 20646337 | doi = 10.1177/039463201002300204 }} 57. ^{{cite journal | vauthors = Wang SY, Calderon J, Kuo Wang G | title = Block of neuronal Na+ channels by antidepressant duloxetine in a state-dependent manner | journal = Anesthesiology | volume = 113 | issue = 3 | pages = 655–65 | date = September 2010 | pmid = 20693878 | doi = 10.1097/ALN.0b013e3181e89a93 }} 58. ^1 2 {{cite web|title=Cymbalta product insert|url=http://pi.lilly.com/us/cymbalta-pi.pdf}} 59. ^{{cite web |url=http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4956388.PN.&OS=PN/4956388&RS=PN/4956388|title=United States Patent 4,956,388: 3-Aryloxy-3-substituted propanamines |vauthors=Robertson DW, Wong DT, Krushinski JH |date=1990-09-11 |work= |publisher=USPTO |access-date=2008-05-17}} 60. ^{{cite journal | vauthors = Wong DT, Robertson DW, Bymaster FP, Krushinski JH, Reid LR | title = LY227942, an inhibitor of serotonin and norepinephrine uptake: biochemical pharmacology of a potential antidepressant drug | journal = Life Sciences | volume = 43 | issue = 24 | pages = 2049–57 | year = 1988 | pmid = 2850421 | doi = 10.1016/0024-3205(88)90579-6 }} 61. ^{{cite journal | vauthors = Bymaster FP, Beedle EE, Findlay J, Gallagher PT, Krushinski JH, Mitchell S, Robertson DW, Thompson DC, Wallace L, Wong DT | title = Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake | journal = Bioorganic & Medicinal Chemistry Letters | volume = 13 | issue = 24 | pages = 4477–80 | date = December 2003 | pmid = 14643350 | doi = 10.1016/j.bmcl.2003.08.079 | url = http://linkinghub.elsevier.com/retrieve/pii/S0960894X03010072 | displayauthors = etal }} 62. ^{{cite web|url=http://www.fda.gov/cder/foi/nda/2004/021427_s000_Cymbalta_AdminCorres.pdf |title=Approval package for: application number NDA 721-427. Administrative/Correspondence #2 |year=2003 |format=PDF |work= |publisher=The FDA Center for Drug Evaluation and Research |pages= |access-date=2008-05-18 }}{{dead link|date=June 2016|bot=medic}}{{cbignore|bot=medic}} 63. ^FDA news 64. ^{{cite web|title=Summary Basis of Decision (SBD): Cymbalta|url=http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2008_cymbalta_110028-eng.php|publisher=Health Canada|date=2008-05-05|access-date=2015-02-27|archive-url=https://web.archive.org/web/20150301073033/http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2008_cymbalta_110028-eng.php|archive-date=2015-03-01|dead-url=yes|df=}} 65. ^{{cite web |url=http://www.thestreet.com/_googlen/stocks/pharmaceuticals/10268662.html?cm_ven=GOOGLEN&cm_cat=FREE&cm_ite=NA |title=Lilly Won't Pursue Yentreve for U.S. |author=Steyer R |date=2006-02-15 |publisher=TheStreet.com |access-date=2008-05-18 |deadurl=yes |archive-url=https://web.archive.org/web/20090202114300/http://www.thestreet.com/_googlen/stocks/pharmaceuticals/10268662.html?cm_ven=GOOGLEN&cm_cat=FREE&cm_ite=NA |archive-date=2009-02-02 |df= }} 66. ^{{cite journal | vauthors = Lenzer J | title = FDA warns that antidepressants may increase suicidality in adults | journal = BMJ | volume = 331 | issue = 7508 | pages = 70 | date = July 2005 | pmid = 16002878 | pmc = 558648 | doi = 10.1136/bmj.331.7508.70-b }} 67. ^{{cite web|url=http://www.news-medical.net/?id=22194|title=FDA approves antidepressant Cymbalta (duloxetine HCl) for treatment of generalized anxiety disorder|date=February 26, 2007|work=News-Medical|access-date=25 December 2013}} 68. ^{{cite web|url=http://www.fiercepharma.com/story/lilly-could-net-15b-plus-cymbalta-extension/2012-07-09|title=Lilly could net $1.5B-plus from Cymbalta extension|last=Staton|first=Tracy|date=July 9, 2012|work=FiercePharma|access-date=25 December 2013}} 69. ^{{cite web|url=http://www.fiercepharma.com/story/eli-lilly-lay-hundreds-sales-cymbalta-nears-edge-patent-cliff/2013-04-11|title=Eli Lilly to lay off hundreds in sales as Cymbalta nears edge of patent cliff|last=Palmer|first=Eric|date=April 11, 2013|work=FiercePharma|access-date=25 December 2013}} 70. ^{{cite news|last1=Hrenchir|first1=Tim|title=10 Most-Prescribed Antidepressant Medications|url=http://www.newsmax.com/Health/Health-Wire/most-prescribed-antidepressant-medications/2015/09/02/id/673123/|work=Newsmax|date=2 September 2015}} 71. ^{{cite web|url=http://americannewsreport.com/nationalpainreport/generic-cheaper-versions-cymbalta-approved-8822633.html|title=Generic Cheaper Versions of Cymbalta Approved|last=Anson|first=Pat|date=December 12, 2013|work=National Pain Report|access-date=January 2, 2014}} External links
7 : Serotonin-norepinephrine reuptake inhibitors|Eli Lilly and Company|Thiophenes|Naphthol ethers|Amines|RTT|Antidepressants |
||||||||||||||
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。